One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
Amgen Inc (AMGN) News
Latest headlines that mention AMGN, newest first · each headline opens the original publisher
- Last price
- $407.44
- Day change
- -1.37%
- Next earnings
- 2026-11-03
AMGN headlines
last 30 daysAmgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment. The post Amgen Boasts Success In Sjogren's; Shares Charge Ahead appeared first on Investor's Business Daily .
A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market's.
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
President Donald Trump doubled down on his $5,000 dividend pledge at the Amgen Irish Open, saying the U.S. is bringing in enough revenue to cover payments to all adults.
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
Also mentioned with AMGN
30dHeadlines that tag both tickers
AMGN news alerts
Get an alert by email or push when a new headline mentions AMGN.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.